Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
Graduate School of Biomedical SciencesThompson Lab
Program in Chemical Biology
Department of Biochemistry and Molecular Pharmacology
Document Type
Journal ArticlePublication Date
2020-01-16Keywords
NAD(+)SARM1
neurodegeneration
therapeutics
Amino Acids, Peptides, and Proteins
Biochemistry
Enzymes and Coenzymes
Medicinal-Pharmaceutical Chemistry
Molecular and Cellular Neuroscience
Molecular Biology
Nervous System Diseases
Therapeutics
Metadata
Show full item recordAbstract
Wallerian degeneration is a neuronal death pathway that is triggered in response to injury or disease. Death was thought to occur passively until the discovery of a mouse strain, i.e., Wallerian degeneration slow (WLD(S)), which was resistant to degeneration. Given that the WLD(S) mouse encodes a gain-of-function fusion protein, its relevance to human disease was limited. The later discovery that SARM1 (sterile alpha and toll/interleukin receptor [TIR] motif-containing protein 1) promotes Wallerian degeneration suggested the existence of a pathway that might be targeted therapeutically. More recently, SARM1 was found to execute degeneration by hydrolyzing NAD(+). Notably, SARM1 knockdown or knockout prevents neuron degeneration in response to a range of insults that lead to peripheral neuropathy, traumatic brain injury, and neurodegenerative disease. Here, we discuss the role of SARM1 in Wallerian degeneration and the opportunities to target this enzyme therapeutically.Source
Loring HS, Thompson PR. Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases. Cell Chem Biol. 2020 Jan 16;27(1):1-13. doi: 10.1016/j.chembiol.2019.11.002. Epub 2019 Nov 21. PMID: 31761689; PMCID: PMC6980728. Link to article on publisher's site
DOI
10.1016/j.chembiol.2019.11.002Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29439PubMed ID
31761689Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.chembiol.2019.11.002